Souhaitez-vous accéder aux communiqués récents ?

New York, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of...

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" has been added to ...

EXTON, PA, June 17, 2025 (GLOBE NEWSWIRE) -- According to Spherix Global Insights’ newly published Special Topix™: Interstitial Lung Disease in Rheumatology (US) report, both rheumatologists and...

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).

Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE)...

CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...